Nitric oxide: Friendly rivalry in tuberculosis

Current Signal Transduction Therapy

Volumn 2, Issue 2, 2007, Pages 121-128

  Mukhopadhyay, Sangita ^a   Nair, Shiny ^a   Hasnain, Seyed E ^a,b,c  

^a CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

^b JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

^c UNIVERSITY OF HYDERABAD   (India)

Author keywords

Immunoregulation; Interleukin 12; Macrophage; Mycobacterium tuberculosis; Nitric oxide; Th1 Th2

Indexed keywords

ANTIINFECTIVE AGENT; BCG VACCINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 8; ISONIAZID; NITRIC OXIDE; NITRIC OXIDE ANTAGONIST; NITRIC OXIDE SYNTHASE INHIBITOR; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; APOPTOSIS; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; TH1 CELL; TH2 CELL; TUBERCULOSIS;

EID: 34249318069     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436207780619536     Document Type: Review

References (156)

1. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-50.
2. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997; 100: 2417-23.
3. Bogdan C. The function of nitric oxide in the immune system. In Handbook of Experimental Pharmacology.Volume: Nitric Oxide (ed. Mayer, B.) 2000; 443-92.
4. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide a physiologic messenger. Ann Intern Med 1994; 120: 227-37.
5. Bogdan C. The multiplex function of nitric oxide in (auto) immunity. J Exp Med 1998; 187: 1361-5.
6. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
7. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003; 54: 469-87.
8. Liew FY, Cox FE. Nonspecific defense mechanisms: The role of nitric oxide. Immunol Today 1991; 12: A17-21.
9. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-64.
10. MacMicking JD, Nathan C, Hom G, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81: 641-50.
11. Fang FC. Mechanism of nitric oxide related anti microbial activity. J Clin Invest 1997; 99: 2818-25.
12. Lowenstein CJ. NO news is good news. Proc Natl Acad Sci USA 1999; 96: 10953-4.
13. Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543-55.
14. Xie K, Dong Z, Fidler IJ. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol 1996; 59: 797-803.
15. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian host and microbial pathogens. Proc Natl Acad Sci USA 2000; 97: 8841-8.
16. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci USA 2001; 98: 3583-8.
17. Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am J Respir Cell Mol Biol 1998; 19: 513-21.
18. Stuehr DJ, Marletta MA. Induction of nitrite/nitrate synthesis BCG infection, lymphokines in murine macrophages by or interferon-γ. J Immunol 1987; 139: 518-25.
19. Hauser B, Radermacher P, Thiemermann C, Matejovic M. Nitric oxide, bacteria, and host defense in sepsis: Who needs what? Shock 2004; 22: 588-90.
20. Denis M. Interferon-γ-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol 1991; 132: 150-7.
21. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175: 1111-22.
22. Chan J, Tanaka K, Caroll D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 1995; 63: 736-40.
23. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad. Sci USA 1997; 94: 5243-8.
24. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679-91.
25. Chan ED, Chan J, Schluger NW. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am J Respir Cell Mol Biol 2001; 25: 606-12.
26. Shiloh MU, Nathan CF. Reactive nitrogen intermediates and the pathogenesis of Salmonella and myrobacteria. Curr Opin Microbiol 2000; 3: 35-42.
27. Huang FP, Niedbala W, Wei XQ, et al. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur J Immunol 1998; 28: 4062-70.
28. Mukhopadhyay S, George A, Bal V, Ravindran B, Rath S. Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction. J Immunol 1999; 163: 1786-92.
29. Taylor-Robinson AW, Liew FY, Severn A, et al. Regulation of immuneresponse by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 980-4.
30. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunol Today 1995; 16: 128-30.
31. Niedbala W, Wei XQ, Piedrafita D, Xu D, Liew FY. Effects of nitric oxide on induction and differentiation of Th1 cells. Eur J Immunol 1999; 29: 2498-505.
32. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-54.
33. Jouanguy E, Doffinger R, Dupuis S, Pallier A, Altare F, Casanova JL. IL-12 and IFN-γ in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol 1999; 11: 346-51.
34. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-86.
35. Ahmed N, Hasnain SE. Genomics of Mycobacterium tuberculosis: old threats & new trends. Indian J Med Res 2004; 120: 207-12.
36. Chakhaiyar P, Hasnain SE. Defining the mandate of tuberculosis research in a postgenomic era. Med Princ Pract 2004; 13: 177-84.
37. Kaufmann SH, Flesch IE. The role of T-cell-macrophage interactions in tuberculosis. Springer Semin Immunopathol 1988; 10: 337-58.
38. Fenton MJ, Vermeulen MW. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect Immun 1996; 64: 683-90.
39. Wang CH, Liu CY, Lin HC, Yu CT, Chung KF, Kuo HP. Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. Eur Respir J 1998; 11: 809-15.
40. Fremond CM, Nicolle DM, Torres DS, Quesniaux VF. Control of Mycobacterium bovis BCG infection with increased inflammation in TLR4-deficient mice. Microbes Infect 2003; 5: 1070-81.
41. Nicolle D, Fremond C, Pichon X, et al. Long-term control of Mycobacterium bovis BCG infection in the absence of Toll-like receptors (TLRs): investigation of TLR2-, TLR6-, or TLR2-TLR4-deficient mice. Infect Immun 2004; 72: 6994-7004.
42. Cho HJ, Xie QW, Calaycay J, et al. Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med 1992; 176: 599-604.
43. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996; 79: 363-80.
44. Pellacani A, Wiesel P, Razavi S, et al. Down-regulation of high mobility group-I (Y) protein contributes to the inhibition of nitric oxide synthase 2 by transforming growth factor-β1. J Biol Cbem 2001; 276: 1653-9.
45. Kleinert H, Schwarz PM, Forstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem 2003; 384: 1343-64.
46. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001; 11: 66-75.
47. Dube RJ, Evans GA, Erwin RA, Kirken RA, Cox GW, Farrar WL. Nitric oxide and thiol redox regulation of Janus kinase activity. Prot Natl Acad Sci USA 1998; 95: 126-31.
48. Karaghiosoff M, Neubauer H, Lassnig C, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13: 549-60.
49. Chakravortty D, Kato Y, Sugiyama T, et al. The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW264.7 macrophage cells: a role of Raf-1 in lipopolysaccharide signaling. J Immunol 2001; 166: 2011-7.
50. Chan ED, Morris KF, Belisle JT, et al. Induction of inducible nitric oxide synthase-NO by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK, MKK7-JNK and NF-κB signaling pathways. Infect Immun 2001; 69: 2001-10.
51. Kristof AS, Marks-Konczalik J, Moss J. Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem 2001; 276: 8445-52.
52. Schindler H, Bogdan C. NO as a signaling molecule: effects on kinases. Int Immunopharmacol 2001; 1: 1443-55.
53. Diaz-Guerra MJ, Castrillo A, Martin-Sanz P, Bosca L. Negative regulation by protein tyrosine phosphatase of IFN-γ-dependent expression of inducible nitric oxide synthase. J Immunol 1999; 162: 6776-83.
54. Diaz-Guerra MJ, Castrillo A, Martin-Sanz P, Bosca L. Negative regulation by phosphatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J Immunol 1999; 162: 6184-90.
55. Peng HB, Libby P, Liao JK. Induction and stabilization of IκBa by nitric oxide mediates inhibition of NF-κB. J Biol Chem 1995; 270: 14214-9.
56. Connelly C, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation of NF-κB activity underlies the pro and anti-inflammatory actions of nitric oxide. J Immunol 2001; 166: 3873-81.
57. Stuehr DJ, Marletta MA. Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res 1987; 47: 5590-4.
58. Bertholet S, Tzeng E, Felley-Bosco E, Mauel J. Expression of the inducible NO synthase in human monocytic U937 cells allows high output nitric oxide production. J Leukoc Biol 1999; 65: 50-8.
59. Jagannath C, Actor JK, Hunter RL Jr. Induction of nitric oxide in human monocytes and monocyte cell lines by Mycobacterium tuberculosis. Nitric Oxide 1998; 2: 174-86.
60. Nicholson S, Bonecini-Almeida Mda G, Lapa e Silva JR, et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996; 183: 2293-302.
61. Wang CH, Lin HC, Liu CY, et al. Up regulation of inducible nitric oxide synthase and cytokine secretion in peripheral blood monocytes from pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2001; 5: 283-91.
62. Kuo HP, Wang CH, Huang KS, et al. Nitric oxide modulates interleukin-1β and tumor necrosis factor-α synthesis by alveolar macrophages in pulmonary tuberculosis. Am J Respir Crit Care Med 2000; 161: 192-9.
63. Friedman CR, Quinn GC, Kreiswirth BN, et al. Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis. J Infect Dis 1997; 176: 478-84.
64. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992; 89: 3030-4.
65. Lepoivre M, Fieschi F, Coves J, Thelander L, Fontecave M. Inactivation of ribonucleotide reductase by nitric oxide. Biochem Biophys Res Commun 1991; 179: 442-8.
66. Brown GC. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995; 369: 136-9.
67. Lizasoain I, Moro MA, Knowles RG, Darley-Usmar V, Moncada S. Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose. Biochem J 1996; 314: 877-80.
68. Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 1998; 95: 7631-6.
69. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157: 87-94.
70. Dimmeler S, Lottspeich F, Brune B. Nitric oxide causes ADP-ribosylation and inhibition of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1992; 267: 16771-4.
71. Actor JK, Olsen M, Jagannath C, Hunter RL. Relationship of survival, organism containment and granuloma formation in acute murine tuberculosis. J Interferon Cytokine Res 1999; 19: 1183-93.
72. Ehlers S, Kutsch S, Benini J, et al. NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads. Immunology 1999; 98: 313-23.
73. Facchetti F, Vermi W, Fiorentini S, et al. Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Am J Pathol 1999; 154: 145-52.
74. Andrew PJ, Harant H, Lindley IJ. Nitric oxide regulates IL-8 expression in melanoma cells at the transcriptional level. Biochem Biophys Res Commum 1995; 214: 949-56.
75. Zouki C, Jozsef L, Ouellet S, Paquette Y, Filep JG. Peroxynitrite mediates cytokine-induced IL-8 gene expression and production by human leukocytes. J Leukoc Biol 2001; 69: 815-24.
76. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/ interluekin-8, novel cytokine that activates neutrophils, J Clin Invest 1989; 84: 1045-9.
77. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-6.
78. Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 1998; 9: 9-23.
79. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-23.
80. Friedland JS, Shattock RJ, Johnson JD, Remick DG, Holliman RE, Griffin GE. Differential cytokine gene expression and secretion after phagocytosis by a human monocytic cell line of Toxoplasma gondii compared with Mycobacterium tuberculosis. Clin Exp Immunol 1993; 91: 282-6.
81. Bergeron A, Bonay M, Kambouchner M, et al. Cytokine patterns in tuberculous and sarcoid granulomas: correlations with histopathologic features of the granulomatous response. J Immunol 1997; 159: 3034-43.
82. Kurashima K, Mukaida N, Fujimura M, et al. Elevated chemokine levels in bronchoalveolar lavage fluid of tuberculosis patients. Am J Respir Crit Care Med 1997; 155: 1474-7.
83. Casarini M, Ameglio F, Alemanno L, et al. Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am J Respir Crit Care Med 1999; 159: 143-8.
84. Pace E, Gjomarkaj M, Melis M, et al. Interleukin-8 induces lymphocyte chemotaxis into the pleural space. Role of pleural macrophages. Am J Respir Crit Care Med 1999; 159: 1592-9.
85. Yamada Y, Nakamura A, Hosoda M, et al. Cytokines in pleural liquid for diagnosis of tuberculous pleurisy. Respir Med 2001; 95: 577-81.
86. Stenger S, Modlin RL. T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin Microbiol 1999; 2: 89-93.
87. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995; 181: 1569-74.
88. Windhagen A, Scholz C, Hollsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995; 2: 373-80.
89. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-98.
90. Trinchieri G. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-γ). Curr Opin Immunol 1997; 9: 17-23.
91. + T cells. J Immunol 1995; 154: 5071-9.
92. Magram J, Connaughton SE, Warrier RR, et al. IL-12-deficient mice are defective in IFN-γ production and type 1 cytokine responses. Immunity 1996; 4: 471-81.
93. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 2005; 175: 5-14.
94. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-48.
95. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-93.
96. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon γ gene-disrupted mice. J Exp Med 1993; 178: 2243-7.
97. Romani L, Puccetti P, Bistoni F. Interleukin-12 in infectious disease. Clin Microbiol Rev 1997; 10: 611-36.
98. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19: 491-4.
99. Baliko Z, Szereday L, Szekeres-Bartho J. Th2 biased immune response in cases with active Mycobacterium tuberculosis infection and tuberculin anergy. FEMS Immunol Med Microbiol 1998; 22: 199-204.
100. Wilsher ML, Hagan C, Prestidge R, Wells AU, Murison G. Human in vitro immune responses to Mycobacterium tuberculosis. Tuber Lung Dis 1999; 79: 371-7.
101. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9: 532-62.
102. Clerici M, Shearer GM, Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/ TH2 paradigm. J Natl Cancer Inst 1998; 90: 261-3.
103. Lohoff M, Gessner A, Bogdan C, Rollinghoff M. The Th1/Th2 paradigm and experimental murine leishmaniasis. Int Arch Allergy Immunol 1998; 115: 191-202.
104. Xing Z, Wang J. Consideration of cytokines as therapeutics agents or targets. Curr Pharm Des 2000; 6: 599-611.
105. Ikeda H, Chamoto K, Tsuji T, et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004; 95: 697-703.
106. Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, Orme IM. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995; 84: 423-32.
107. Kobayashi K, Yamazaki J, Kasama T, et al. Interleukin (IL)-12 deficiency in susceptible mice infected with Mycobacterium avium and amelioration of established infection by IL-12 replacement therapy. J Infect Dis 1996; 174: 564-73.
108. De Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280: 1435-8.
109. Rook GA, Seah G, Ustianowski A. M. tuberculosis: immunology and vaccination. Eur Respir J 2001; 17: 537-57.
110. Wakeham J, Wang J, Magram J, et al. Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis bacille Calmette-Guerin in IL-12-deficient mice. J Immunol 1998; 160: 6101-11.
111. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997; 186: 39-45.
112. Cooper AM, Kipnis A, Turner J, Magram J, Ferrante J, Orme IM. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol 2002; 169: 1322-7.
113. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280: 1432-5.
114. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998; 160: 5428-35.
115. Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 2005; 5: 661-7.
116. Hernandez-Pando R, Pavon L, Arriaga K, Orozco H, Madrid-Marina V, Rook G. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte. Infect Immun 1997; 65: 3317-27.
117. Hernandez-Pando R, Orozcoe H, Sampieri A, et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89: 26-33.
118. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
119. Bingisser MR, Holt PG. Immunomodulating mechanisms in the lower respiratory tract: nitric oxide mediated interactions between alveolar macrophages, epithelial cells, and T-cells. Swiss Med Wkly 2001; 131: 171-9.
120. Kwak H, Yang YS, Pae HO, Kim YM, Chung HT. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of Th1-dependent immune response. Mol Cells 2001; 12: 178-84.
121. Wei XQ, Charles IG, Smith A, et al. Altered immune response in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-11.
122. Mukhopadhyay S, Saboo P, George A, Bal V, Rath S, Ravindran B. Delayed clearance of filarial infection and enhanced Th1 immunity due to modulation of macrophage APC functions in xid mice. J Immunol 1999; 163: 875-83.
123. Mukhopadhyay S, Srivastava VM, Murthy PK, Hasnain SE. Poorer NF-κB signaling by microfilariae in macrophages from BALB/c mice affects their ability to produce cytotoxic levels of nitric oxide to kill microfilariae. FEBS Lett 2004; 567: 275-80.
124. Xiong H, Zhu C, Li F, et al. Inhibition of interleukin-12 p40 transcription and NF-κB activation by nitric oxide in murine macrophages and dendritic cells. J Biol Chem 2004; 279: 10776-83.
125. Allione A, Bernabei P, Bosticardo M, Ariotti S, Forni G, Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-γ-dependent and IFN-γ independent induction of apoptosis. J Immunol 1999; 163: 4182-91.
126. Henson SE, Nichols TC, Holers VM, Karp DR. The ectoenzyme γ-glutamyl transpeptidase regulates antiproliferative effects of S-nitrosoglutathione on human T and B-lymphocytes. J Immunol 1999; 163: 1845-52.
127. Vig M, Srivastava S, Kandpal U, et al. Inducible nitric oxide synthase in T cells regulates T cell death and immune memory. J Clin Invest 2004; 113: 1734-42.
128. Bidere N, Senik A. Caspase-independent apoptotic pathways in T lymphocytes: a minireview. Apoptosis 2001; 6: 371-5.
129. Moulian N, Truffault F, Gaudry-Talarmain YM, Serraf A, Berrih-Aknin S. In vivo and in vitro apoptosis of human thymocytes are associated with nitrotyrosine formation. Blood 2001; 97: 3521-30.
130. Hildeman DA, Mitchell T, Teague TK, et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 1999; 10: 735-44.
131. Nabeshima S, Nomoto M, Matsuzaki G, et al. T cell hyporesponsiveness induced by activated macrophages through nitric oxide production in mice infected with Mycobacterium tuberculosis. Infect Immun 1999; 67: 3321-6.
132. Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon γ eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000; 192: 117-22.
133. Hoffman R, Mahidhara RS, Wolf-Johnston AS, Lu L, Thomson AW, Simmons RL. Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells. Transplantation 2002; 74: 836-45.
134. Fiorucci S, Mencarelli A, Distrutti E, Baldoni M, Soldato P, Morelli A. Nitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs. J Immunol 2004; 173: 874-82.
135. Deakin AM, Payne AN, Whittle BJ, Moncada S. The modulation of IL-6 and TNF-α release by nitric oxide following stimulation of J774 cells with LPS and IFN-γ. Cytokine 1995; 7: 408-16.
136. Kim YM, Talanian RV, Li J, Billiar TR. Nitric oxide prevents IL-1β and IFN-γ-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1β-converting enzyme). J Immunol 1998; 161: 4122-8.
137. Vodovotz Y, Chesler L, Chong H, et al. Regulation of transforming growth factor β1 by nitric oxide. Cancer Res 1999; 59: 2142-9.
138. Wang S, Wang W, Wesley RA, Danner RL. A Sp1 binding site of the tumor necrosis factor α promoter functions as a nitric oxide response element. J Biol Chem 1999; 274: 3390-3.
139. Doffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-γ receptor signaling chain deficiency in a patient with Bacille Calmette-Guerin and Mycobacterium abcessus infection. J Infect Dis 2000; 181: 379-84.
140. Vilcek J, Klion A, Henriksen-DeStefano D. Defective gamma-interferon production in peripheral blood leucocytes of patients with acute tuberculosis. J Clin Immunol 1986; 6: 146-51.
141. Gomes SM, Florido M, Pais TF, Appelberg R. Improved clearance of Mycobacterium avium upon disruption of the inducible nitric oxide synthase gene. J Immunol 1999; 162: 6734-9.
142. Yu K, Mitchell C, Xing Y, Magliozzo RS, Bloom BR, Chan J. Toxicity of nitrogen oxides and related oxidants on mycobacteria: M. tuberculosis is resistant to peroxynitrite anion. Tuber Lung Dis 1999; 79: 191-8.
143. Firmani MA, Riley LW. Mycobacterium tuberculosis CDC1551 is resistant to reactive nitrogen and oxygen intermediates in vitro. Infect Immun 2002; 70: 3965-8.
144. O'Brien L, Carmichael J, Lowrie DB, Andrew PW. Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect Immun 1994; 62: 5187-90.
145. Rhoades ER, Orme IM. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect Immun 1997; 65: 1189-95.
146. Da Silva TR, De Freitas JR, Silva QC, et al. Virulent Mycobacterium fortuitum restricts NO production by a gamma interferon-activated J774 cell line and phagosome-lysosome fusion. Infect Immun 2002; 70: 5628-34.
147. Firmani MA, Riley LW. Reactive nitrogen intermediates have a bacteriostatic effect on Mycobacterium tuberculosis in vitro. J Clin Microbiol 2002; 40: 3162-6.
148. Zahrt TC, Deretic V. Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid Redox Signal 2002; 4: 141-59.
149. Ehrt S, Shiloh MU, Ruan J, et al. A novel antioxidant gene from Mycobacterium tuberculosis. J Exp Med 1997; 186: 1885-96.
150. Leal IS, Smedegard B, Andersen P, Appelberg R. Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-γ generation. Immunology 2001; 104: 157-61.
151. Skinner MA, Ramsay AJ, Buchan GS, et al. A DNA prime-live vaccine boost strategy in mice can augment IFN-γ responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 2003; 108: 548-55.
152. Timmins GS, Master S, Rusnak F, Deretic V. Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo. J Bacteriol 2004; 186: 5427-31.
153. Timmins GS, Master S, Rusnak F, Deretic V. Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 3006-9.
154. Nakagawa T, Yamane H, Takayama M, Sunami K, Nakai Y. Involvement of nitric oxide in aminoglycoside vestibulotoxicity in guinea pigs. Neurosci Lett 1999; 267: 57-60.
155. Shewade Y, Tirth S, Bhonde RR. Pancreatic islet-cell viability, functionality and oxidative status remain unaffected at pharmacological concentrations of commonly used antibiotics in vitro. J Biosci 2001; 26: 349-55.
156. Baydoun AR, Wileman SM, Wheeler-Jones CPD, et al. Transmembrane signalling mechanisms regulating expression of cationic amino acid transporters and inducible nitric oxide synthase in rat vascular smooth muscle cells. Biochem J 1999; 344: 265-72.